Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®

• Status: Completed
• Trial end date: 2022-11-13
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to assess bioequivalence between a single oral dose from the test product Metformin / Vildagliptin tablets (1000 mg as metformin hydrochloride / 50 mg as vildagliptin) manufactured by Pharmaceutical Arab Industries Society, Tunisia versus the reference product Galvumet® tablets (1000 mg as metformin hydrochloride / 50 mg as vildagliptin) manufactured by Novartis.

This study also aims to monitor the safety of the subjects. This study is an open label, randomized, fed, single oral dose, two-treatment, two-sequence, and two-period crossover study with a washout interval of at least one week between dosing.

Eighteen (18) Tunisian subjects will be enrolled for this study. Subjects will be healthy volunteers, adults, aged between eighteen to fifty (18-50) years, (both inclusive), within the accepted limits for body height & weight and meeting the selection criteria for this study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Reseach Laboratory of Clinical and Experimental Pharmacology
• Collaborators: Centre National Chalbi Belkahia de Pharmacovigilance-Tunisie; La Société Arabe des Industries Pharmaceutiques-Tunisie
• Treatments: Metformin; Vildagliptin

Criteria

Inclusion Criteria:

A. The subject is aged between eighteen to fifty years (18 - 50), both inclusive.

B. The subject is within the limits for his height & weight as defined by the body mass index (BMI) range (18.5 - 30.0 Kg/m2).

C. The subject is able to understand and willing to sign the Informed Consent Form.

D. The subject has completed his Coronavirus 19 vaccination schedule. E. The subject is willing to undergo the necessary medical examinations pre- during & post-study.

F. There is no evidence of psychiatric disorder, antagonistic personality, and poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.

G. The results of medical history, physical examination, vital signs, conducted medical laboratory tests & ECG recording are normal as determined by the investigator.

H. The subject tested negative for Hepatitis B (HBsAg) and Hepatitis C (HCVAb). I. For female subjects: negative pregnancy test and the woman is using two reliable contraception methods and should be non-lactating.

Non-inclusion Criteria:

A. The subject is a heavy smoker (more than 10 cigarettes per day). B. The subject has a history of or concurrent abuse of alcohol. C. The subject has a history of or concurrent abuse of illicit drugs. D. The subject has a history of hypersensitivity and/or contraindications to the study drug and any related compounds.

E. The subject is vegetarian. F. The subject has suffered an acute illness within seven (7) days before first dosing (declared before inclusion).

G. The subject has been hospitalized within three (3) months before the study. H. The subject has taken a prescription medication within two weeks or even an over-the-counter product (OTC) within seven (7) days before first dosing.

I. The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before first dosing (declared before inclusion).

J. The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinal, immunological, dermatological, neurological, musculoskeletal or psychiatric diseases.

K. The subject has been participating in any clinical study (e.g. PKs, BA and BE studies) within the last 80 days prior to the present study.

L. The subject has donated blood within 80 days before first dosing.

Exclusion Criteria:

A. The subject has suffered an acute illness within seven (7) days before dosing (declared after inclusion).

B. The subject has been hospitalized during the study. C. The subject has consumed caffeine or xanthine containing beverages or foodstuffs within two (2) days before dosing and until 12 Hrs after dosing in both study periods.

D. The subject has taken a prescription medication within two (2) weeks or even an OTC within seven (7) days before first dosing and any time during the study unless otherwise judged acceptable by the investigator.

E. The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before dosing (declared after inclusion) and any time during the study.

F. The subject underwent a radiological examination with an injection of Iodinated Contrast Media within 48 hours before first dosing.

G. The subject has a positive Covid-19 rapid test.